Ablynx spikes as PhIII aTTP study comes through with promising data, setting up an FDA application
Ablynx shares {$ABLX BB} surged 25% this morning after the Belgian biotech reported that its lead drug for an ultra-rare blood clotting disease hit the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
